July 17, 2019
1 min read

Harvoni joins growing DAA options for younger patients with HCV

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Harvoni joins other direct-acting antivirals in demonstrating safety and high efficacy in younger pediatric patients with chronic hepatitis C, specifically those aged 3 years to younger than 6 years, according to results published in Hepatology.

“In children who become chronically infected, the course of infection is usually slower than in adults; however, liver disease can progress during early life, and cases of cirrhosis, hepatocellular carcinoma, and end-stage liver disease requiring liver transplantation in childhood have been reported,” Kathleen B. Schwarz, MD, from Johns Hopkins Hospital in Maryland, and colleagues wrote. “The availability of an all-oral, direct-acting antiviral regimen for young children with chronic HCV infection would represent a significant advance in the care of patients who currently have limited treatment options.”

The study comprised 34 pediatric patients who received treatment with Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) during the 2017 year. Patients were treatment-naive and had no known cirrhosis.

The overall sustained virologic response was 97%. One patient, aged 3 years, discontinued treatment due to an adverse event of “abnormal drug taste” and experienced grade 1 vomiting after administration of the drug.

Twenty-five patients experienced at least one adverse event, most commonly vomiting (24%), cough (21%) and pyrexia (21%). No patient experienced a serious adverse event.

Schwarz and colleagues also noted that study treatment did not affect pubertal development through 12 weeks of posttreatment follow-up.

“There remains a significant unmet medical need for an all-oral, interferon-free, direct-acting antiviral regimen for younger children,” the researchers wrote in reference to poor outcomes in pediatric patients treated with interferon. “Similar to prior observations in children 6 to [younger than] 18 years old, treatment with ledipasvir-sofosbuvir was well tolerated in this younger population.” – by Talitha Bennett

Disclosure: Schwarz reports she has received grants from Bristol-Myers Squibb, Gilead and Roche/Genentech; consults for Gilead, Roche/Genentech and UpToDate; and that the study was funded by Gilead Sciences. Please see the full study for all other authors’ relevant financial disclosures.